Ibio, Inc. · NASDAQ:IBIO
Ibio — Investor Presentation (January 2024)
66 slides from Ibio's investor presentation, Jan 8, 2024
Slide 1: Tomorrow's Precision Antibody Therapeutics Powered by Machine Learning
January 2024 Tomorrow’s Precision Antibody Therapeutics Powered by Machine Learning
Slide 2: Forward-looking Statements
2 Forward-looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continu
Slide 3: Developing antibodies for next generation of difficult targets
* U.S. Patent No. 11,545,238 3 We are developing antibodies for the next generation of difficult targets and modes of action with the goal of engineering high developability and enhanced safety into our molecules
Slide 4: Technology Can Unlock the Next Phase in a Maturing Antibody Market
https://www.globenewswire.com/news-release/2023/09/06/2738625/0/en/Monoclonal-Antibodies-Market-is-expected-to-reach-USD-612-2-Billion-by-2032-growing-at-a-CAGR-of-12-3-from-2022-to-2032.html Lyu, X. et al. The global landscape of approved antibody therapies. Antibody Therapeutics 5, 233–257 (2022).
Slide 5: Vast Areas of the Human Surfaceome Remain Untapped by Antibodies
1 Bausch-Fluck et al., PNAS, October 2018 2 Charles River, Retrogenix Human Protein Library 3 Lyu et al., Antibody Therapeutics, September 2022 5 Vast Areas of the Human Surfaceome Remain Untapped by Antibodies 91 Approved Antibodies3 2,886 >6,500 In silico predicted cell surface proteins1 membrane
Slide 6: Today's Ab Market Challenge: Complex Targets, Safety & Developability Issues
The era of low-hanging fruit is over-saturated Existing techniques do not address increasing target complexity and modes of actions ADCs and bispecifics have proven successful but revealed off-tissue safety concerns Antibody developability has surfaced as critical hurdles 6 Today’s Ab Market Challen
Slide 7: iBio's Technology Platform Aims to Solve Key Issues of mAb Discovery
7 iBio’s Technology Platform Aims to Solve Today’s Key Issues of mAb Discovery and Development Epitope Steering Technology reliably unlocks antibodies for challenging targets StableHu™ and mammalian display technologies synergize to slash mAb optimization to under 4 weeks and create the EngageTx™ T-
Slide 8: Unlocking High-Value Drug Targets: AI-Engineered Epitopes
Match Engineered Structure to Target Refined for Greater Stability Optimized for Water Solubility Unlocking High-Value Drug Targets: AI-Engineered Epitopes are Generalizable to a Broad Set of Complex Structural Drug Binding Sites Junctional Epitopes Complex Secondary Structures Membrane Proteins (e.
Slide 9: StableHu Antibody Optimization & Mammalian Display Screening
Input Antibody StableHu AI-Engine Mammalian Display Output Antibody Template CDR Predict library of human CDR variants Single-cell screen mammalian display CDR library Optimized antibody with fully human CDRs Accelerate Success: StableHu Antibody Optimization & Mammalian Display Screening Propel Fas
Slide 10: EngageTx, a CD3-Based T-Cell Engager Panel
10 EngageTx, a CD3-Based T-Cell Engager Panel, Addresses 3 Key Challenges: Cytokine Release, NHP Cross-Reactivity and Immunogenicity Risk Numerous tumor antigen arms Diverse CD3 engager arms 1 Sequence Diversity 2 Hu-Cyno Cross-Reactivity 3 Range of Cytokine Release Increased humanness and broad CD3
Slide 11: Smart Antibodies: ShieldTx Conditionally Activated Antibodies
11 “Smart” Antibodies: ShieldTx Conditionally Activated Antibodies Strive to Improve Safety by Selectively Targeting Diseased but not Healthy Tissue H+ Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue “On-epitope, on-tissue” therapy DME activation Diseased Tissue “On epitope, on tissu
Slide 12: iBio's Platform Tackles Discovery Challenges for the Next Era of Antibodies
Epitope Engineering Engine* Proprietary Antibody Library AI-powered mammalian-display co-optimization of mono/multi-specific antibody and conditionally activated mask Engineered Epitope Steering AI-powered engineering of conformational epitopes Epitope-specific antigens that steer discovery to inten
Slide 13: Capitalizing on AI: Focused, Capital Efficient Business Plan
AI Discovery Platform Proprietary Pipeline • Advancing a select few “fast followers” • Potential licensing and asset sales for other molecules Third Party Collaboration • Potential for upfront technology access fee and milestones plus royalties for multiple targets Capitalizing on AI: We Believe Our
Slide 14: Strategic Partnerships
Partner existing molecules or discovery projects against new targets Strategic Partnerships 14 Partners and Collaborators Trusting in iBio’s Ability to Solve Today’s Drug Discovery Challenges Exclusive licensing for non-core therapeutic areas to 3rd parties (vaccines, etc.) Third Party Collaboration
Slide 15: Technology Stack Spurs Rapid Preclinical Pipeline Growth
EPITOPE STRUCTURES Loop Display Junctional Epitopes Complex Secondary Structures Membrane Proteins PROGRAMS PRE-CLINICAL CLINICAL Mode of Action IBIO-101 Protein Complex Stabilization Trop-2 x CD3* Conditional Activation MUC16 Conditional Activation Target 5 TBA EGFRvIII Tumor Specific Epitopes CCR8
Slide 16: Market-Tested Potential: Competitor Early-Stage Deals
* Acquisition / Merger + License or collaboration 16 Market-Tested Potential: Competitor Early-Stage Deals Signal Promising Opportunities for Our Pipeline Pre-2019 2020 2021 2022 CCR8 Gilead / Jounce+ : $85M upfront, $35M equity investment, $685M milestones SEP 2020 FEB 2021 PD-1 agonist Merck / Pan
Slide 17: iBio Company Highlights
17 iBio Company Highlights • Ticker: IBIO (NYSE-A); 3,655,036 shares outstanding as of 12/6/23* • Reduced costs by ~68% post CDMO divestment from FY 23 Q1 to Q4 • Majority of debt secured by property for sale in Bryan, TX Financial AI-driven discovery tech stack • Patented epitope-engineering techno
Slide 18: Technology Platform & Preclinical Pipeline
Technology Platform & Preclinical Pipeline 18
Slide 19: IBIO-101 IL-2 Sparing Anti-CD25
19 IBIO-101 IL-2 Sparing Anti-CD25
Slide 20: IBIO-101 for Regulatory T-Cell Depletion
Recent Transactions & Milestones *Roche acquisition of Tusk Therapeutics completed for €70M upfront, acquiring worldwide rights to anti-CD25 program. Values converted to dollars as reported in public press releases **Data presented by Roche at AACR 2023 20 IBIO-101 for Regulatory T-Cell (Treg) Deple
Slide 21: IBIO-101 Reduces Tumor Growth by Selectively Depleting Tregs
Data on file. Treg = Regulatory T Cells; Teff = Effector T Cells; ADCC = Antibody Dependent Cellular Cytotoxicity 21 IBIO-101 Reduces Tumor Growth in Preclinical Studies by Selectively Depleting Immunosuppressive Tregs without Affecting Cancer Killing Teffs Indiscriminate depletion of Treg + Teff TU
Slide 22: IBIO-101 Selectively Depletes Tregs while Preserving IL-2 Signaling
RG6292 is Roche’s monoclonal antibody that targets CD25 (IL-2Rα). IBIO-101 data on file. 22 IBIO-101 Selectively Depletes Tregs while preserving IL-2 signaling IBIO-101 potently binds recombinant CD25 which leads to Treg depletion while sparing Teffs 0.0001 0.001 0.01 0.1 1 10 100 0.0 0.5 1.0 1.5 2.
Slide 23: IBIO-101 Increases Teff/Treg Ratio in Preclinical Studies
23 IBIO-101 Increases in Teff/Treg Ratio in Preclinical Studies Inhibiting Tumor Growth Tumor growth inhibition correlates with T-eff/T-reg ratio Potently increases T-eff/T-reg ratio1 0 10 20 30 0 1000 2000 3000 4000 Days Tumor Volume (mm3 ) Negative Control IBIO-101, 0.1 mg/kg IBIO-101, 1.0 mg/kg R
Slide 24: IBIO-101 in Combination With a Checkpoint Inhibitor
24 IBIO-101 in Combination With a Checkpoint Inhibitor Shows Greater Efficacy 0 10 20 30 0 1000 2000 3000 4000 Days Tumor Volume (mm3 ) Negative Control * Anti-PD1, 2.5 mg/kg IBIO-101, 1 mg/kg + anti-PD1, 2.5 mg/kg # IBIO-101, 1.0 mg/kg 0 10 20 30 0 1000 2000 3000 4000 Days Tumor Volume (mm3 ) Negat
Slide 25: IBIO-101 Favorable Characteristics for CMC Development
25 IBIO-101 is an Antibody With Favorable Characteristics for CMC Development • Identified manufacturing partner to produce IBIO-101 for Phase 1&2 clinical trials • Discovered suitable cell lines for manufacturing MCB • Established IBIO-101 CMC methodology for producing high yield, high purity, stab
Slide 26: Anti-CCR8 for the Depletion of T-regulatory Cells
26 Anti-CCR8 High ADCC Anti-CCR8 for the Depletion of T-regulatory Cells
Slide 27: CCR8 for Tumor-Infiltrating Treg Depletion
*Fibrogen / HiFiBio: Fibrogen purchased option to multiple programs in June 2021, then exercised the option for excl. license to CCR8 program in Dec. 2021. **Gilead / Jounce: Exclusive worldwide license to anti-CCR8 antibody. *** Coherus / Surface Oncology: acquisition, announced in June 2023, adds
Slide 28: CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive
Zheng, et al. Cell 169.7 (2017): 1342-1356; Whiteside, et al. Immunology 163(4) (2021): 512-520; Kidani, et al. PNAS 119(7) (2022): e2114282119 28 CCR8+ Treg Cells Are Tumor Infiltrating and Highly Immunosuppressive Depletion of CCR8+ Treg cells has potential to evoke potent tumor immunity • Systemi
Slide 29: Anti-CCR8 Antibody Exhibits High Specificity and Cell Killing
Data on file 29 Afucosylated Anti-CCR8 Antibody Exhibits High Specificity, CCL1 Antagonism and CCR8-Specific Cell Killing High Specificity CCR8 Cell Binding 0.0001 0.001 0.01 0.1 1 10 0 2 4 6 8 10 hCCR8 overexpressed cells Ab. (nM) MFI hIgG1 isotype mIgG2A isotype Anti -hCCR4 - EC50 = NA Anti-mCCR8
Slide 30: CCR8-Specific High ADCC Antibody Induces Tumor Regression
30 iBio’s CCR8-Specific High ADCC Antibody Induces Tumor Regression in a Transgenic Human CCR8 Mouse Model Day -7 Day 0 Day 0, 3, 7, 10 Tumor implantation Subsequent dosing Test article dosing (i.p) 0 2 4 6 8 10 12 14 0 50 100 150 200 250 300 Days after treatment Tumor Volume (mm 3 ) hIgG1 negative
Slide 31: Unlocking Bi-Specific Antibodies with EngageTx CD3 mAb Panel
31 Unlocking the Power of Bi-Specific Antibodies with EngageTx, Our Versatile CD3 mAb Panel Wide Range of Affinities, NHP Cross Reactivity, High Developability
Slide 32: Next Generation Anti-CD3 T Cell Engagers
*Eli Lilly / Merus: Fibrogen Research collaboration using Merus’ proprietary platform to develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies. ** GSK WuXi: License of WuXi’s preclinical CD3 bi-specific, plus 3 earlier stage programs ***Amgen / Teneobio: Teneobio was dev
Slide 33: Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies
Data on file 33 Dual Approaches to a Diverse Panel of Anti-CD3 Antibodies Hu/Cyno CD3 & T Cell TCR CD3 Engineered Epitopes T Cell Template 1 Template 2 Structural-Epitope Immunization & Screening StableHu Optimizer AI Discovery Engine AI-Engineered Immunogens Epitope & T Cell Immunization Epitope &
Slide 34: Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies
Data on file 34 Libraries and Screens Discover Hu-Cyno CD3 Cross-Reactive Antibodies Epitope-Steered Immunization 0 5 10 15 0 2 4 6 Human CD3 ELISA FoldChange / Background Cyno CD3 ELISA FoldChange / Background Immunized Library 1 100 200 Human T Cell Binding Fold Change / Background HIT 0 Human T C
Slide 35: EngageTx Selected for Diversity of T Cell Binding and Activation
Data on file 35 EngageTx is Selected for a Diversity of T Cell Binding and Activation EC50: 3 – 570 nM EC50: 2.5 – 70 nM Human T Cell Binding EC50 (nM) 0.1 1 10 100 0 20 40 60 80 Concentration (nM) IL-2 (pg/mL) Human T Cell Activation M80-H1-1 M80-H1-2 M80-H3-1 M80-L1-1 M80-L2-1 IgG1 Isotype (-) Ctl
Slide 36: ShieldTx Antibody Masking Technology
36 ShieldTx Antibody masking technology for delivering on-epitope, on-tissue clinical candidates with enhanced safety and developability
Slide 37: On-Target-Off-Tissue Side Effects Limit Antibodies
Diseased Tissue Healthy Tissue 37 On-Target-Off-Tissue Side Effects Severely Limit The Potential of Existing And Future Antibodies Even exquisitely specific antibodies fail in clinical trials by doing exactly what they are asked to do – hit the target. The problem often lies in the target being also
Slide 38: Engineered Epitopes Provide Integrated Solution for Masking Antibodies
38 Our Engineered Epitopes Provide an Integrated Solution for Identifying And Subsequently Masking Antibodies Diseased Tissue “On-epitope, off-tissue” therapy Healthy Tissue DME activation “On-epitope, on-tissue” therapy H+ DME: Disease Micro Environment Antibodies are activated by the removal of th
Slide 39: Masked Antibodies: Proven Concept and iBio's Platform Potential
Masked Antibodies are a Proven Concept and iBio’s Platform has the Potential to Solve Key Remaining Challenges 39 THE PROBLEM OUR SOLUTION 1 Separate antibody and mask discovery process is inefficient Co-discovery of epitope-steered antibody and mask is more efficient Discovery process 2 Separate di
Slide 40: Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies
40 Conditionally Activated Anti-MUC16 x CD3 Bispecific Antibodies Targeting the Non-Shed MUC16 Region Leveraging iBio’s Epitope Steering, ShieldTx, and EngageTx Technologies
Slide 41: MUC16 Potentially for Ovarian and Other Cancers
+Regeneron MUC16xCD3 (Sept 2022): Ph. 1 31% ORR Ph. 2 enrollment 41 MUC16 Potentially for Ovarian and Other Cancers Bind a membrane-proximal MUC16 epitope Membrane-proximal binding avoids epitope elimination by tumors Bind a non-glycosylated epitope to avoid altered glycosylation on tumors • Ovarian
Slide 42: MUC16 Is Overexpressed and Shed by Tumor Cells
42 MUC16 Is Overexpressed and Shed by Tumor Cells O-glycosylation N-glycosylation MUC16 epitope shedding Shedding eliminates the epitope and creates an antigen sink for most MUC16 antibodies Antibodies that bind the non-shed domain maintain activity N-terminal and tandem repeat (TR) domains that are
Slide 43: Immunizations Steered to a MUC16 Epitope Avoiding Shedding
Weeks 1–2 Weeks 3–4 Week 5 43 Immunizations Were Steered to a MUC16 Epitope that Avoids Epitope Shedding Engineered Epitope Prime + MUC16 Cell Boost AI Discovery Engine MUC16 Engineered Epitope Structural-epitope Immunization & Screening Engineered Epitope ELISA Screen MUC16 OVCAR-3 MUC16high Cell B
Slide 44: Top Three Hit Clones Bind Non-Glycosylated MUC16 Epitope
44 Top Three Hit Clones Bind the Non-Glycosylated MUC16 Epitope Closest to the Membrane 1D7 8G4 21G6 Hits do not bind shed 230-mer Hits bind non-glycosylated non-shed 29-mer binding time O-glycosylation N-glycosylation N-terminal and tandem repeat (TR) domains that are shed Epitope KD = 8.0 nM KD =
Slide 45: Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Benchmark
45 Top MUC16 Clone 8G4 Binds OVCAR-3 Cells Comparable to Regeneron Benchmark Regeneron benchmark Clone ID: Secondary Only Unstained OVCAR-3 Cells 8G4 top clone higher cell binding Mode Normalized Data on file
Slide 46: 8G4 Clone Maintains Binding in a Fully Human Framework
46 8G4 Clone Maintains OVCAR-3 Cell and MUC16 Epitope Binding in a Fully Human Framework 8G4 with fully human framework reduces immunogenicity risk Glycosylated MUC16 membrane-proximal epitope SPR: KD = 5.1 nM Iso. Ctl OVCAR-3 Cells Epitope binding Cell binding higher cell binding Data on file
Slide 47: Efficient Expression with 2x2 Format Anti-CD3 x MUC16
47 Efficient Expression with 2x2 Format: Anti-CD3 x MUC16 Bispecific T-Cell Engagers scFv-Fc 2x2 Anti-MUC16 TAA Anti-CD3 (EngageTx) CD3 MUC16 TAA T Cell Tumor Cell T Cell mediated killing
Slide 48: Anti-CD3 x MUC16 T Cell Engagers Stimulate T Cells
EC50 = 14 nM EC50 = 62 nM EC50 = 19 nM EC50 = 126 nM Data on file 48 2X2 Anti-CD3 X MUC16 T Cell Engagers Stimulate T Cells in Donor PBMCs EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit CD69 MFI Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms
Slide 49: Anti-CD3 x MUC16 T Cell Engagers Kill OVCAR-3 Cells
EC50 = 4.0 nM EC50 = 2.5 nM EC50 = 5.2 nM EC50 = 5.2 nM Data on file 49 2X2 Anti-CD3 X MUC16 T Cell Engagers Kill OVCAR-3 Ovarian Cancer Cells EC50 >> 100 nM EC50 >> 100 nM MUC16 Arm 1 (-)CD3 Arm only Epitope-Steered Immunized Hit StableHu Hit Concentration (nM) MUC16 Arm 2 CD3 Arms MUC16 Arms % Spe
Slide 50: ShieldTx Mask Conditionally Activates MUC16 and CD3 Hits
Data on file 50 ShieldTx Engineered Epitope Mask Conditionally Activates MUC16 and CD3 Hits Mask Cleavage No Mask Mask (–MMP9) Mask (+MMP9) MMP protease Engineered Epitope Mask Intact Inactive Antibody Active Antibody Anti-MUC16 hit Anti-CD3 hit MUC16 Binding Response CD3 Binding Response time (s)
Slide 51: Anti-Trop-2 x CD3 Bi-Specific Antibody
51 Anti-Trop-2 x CD3 Bi-Specific Antibody against Tumor-Specific Trop-2 Cancer Cells
Slide 52: Trop-2 x CD3 Bi-Specific Antibody
Recent transactions Target mechanism Potential indications Differentiation / opportunity Gilead acquired Immunomedics (Sept 2020): $21Bn Payment Trodelvy: Approval 52 Trop-2 x CD3 Bi-Specific Antibody Potentially for Head & Neck and Other Cancer Select killing cancer cells that up-regulate Trop-2 ex
Slide 53: Trop-2 x CD3 Bi-Specific Antibody Selective Target
Tumor cells show significantly increased Trop-2 expression Tumor cell death with high Trop-2 expression Trop-2 x CD3 binds to tumor cells Trop-2 x CD3 recruits T cells to kill tumor cells 53 Trop-2 x CD3 Bi-Specific Antibody Selective Target Overexpress Trop-2 Cancer Cells Trop-2 Tumor cell Healthy
Slide 54: Trop-2 x CD3 Potently Kills Tumor Cells with Low Cytokine Release
54 iBio’s Trop-2 x CD3 Bi-Specific Antibody Potently Kills Tumor Cells with Low Cytokine Release 54 0.0001 0.001 0.01 0.1 1 10 0 20 40 60 80 100 Ab (nM) % of Cell Killing ID EC50 (pM) Cmax (% killing) SD-753019 1.4 92% SD-231831 7.2 92% SD-753019 (Trop-2 x CD3SP34 Gen1) SD-231831 (Trop-2 x CD3iBio)
Slide 55: Single Dose Induces Tumor Regression in Humanized Mouse Model
55 A Single Dose of iBio’s Bispecific Trop-2 x CD3 Antibody Induces Tumor Regression in a Humanized Mouse Cancer Model 0 7 14 0 50 100 150 200 250 Days after tumor implantation Tumor volume (mm 3 ) Vehicle SD-231831 (1 mg/kg) Trop-2 x CD3iBio * * * * p<0.05 vs vehicle Single dose SD-231831 36% tumor
Slide 56: Anti-EGFRvIII High ADCC mAb
56 Anti-EGFRvIII High ADCC mAb Against Tumor-Specific EGFRvIII Cells
Slide 57: EGFRvIII Potentially for Glioblastoma and Other Cancers
**Seagen / LAVA Therapeutics (Sep 2022): $50M upfront, $650M milestones ***Taiho / Cullinan Oncology (May 2022): $275M upfront, $130M milestones * Pierre Fabre / Scorpion: Scorpion licensed two preclinical-stage programs to Pierre Fabre which are targeted to specific EGFR mutations in lung cancer. *
Slide 58: Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells
Skin toxicity No skin damage 58 iBio’s Anti-EGFRvIII mAbs Selectively Kill EGFRvIII-Positive Tumor Cells and Not EGFR1-Expressing Cells in Healthy Tissues iBio mAb binding specifically to EGFRvIII Tumor Size Reduction iBio mAb doesn’t bind to EGFR1 in skin Non-EGFRvIII specific mAb binds to EGFR1 in
Slide 59: EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells
59 iBio’s EGFRvIII-Selective mAbs Kill Tumor Cells without Affecting Healthy Cells Negative control, EC50 = no binding Cetuximab, EC50 = 0.018 nM SD-233883, EC50 = 0.008 nM SD-710726, EC50 = 0.020 nM 0.0001 0.001 0.01 0.1 1 10 0 20 40 60 80 Antibody Concentration (nM) % Of Tumor Cell Killing (higher
Slide 60: EGFRvIII-Specific Antibody Inhibits Tumor Growth in Xenograft Model
60 iBio’s EGFRvIII-Specific High-ADCC Antibody Inhibits Tumor Growth in an EGFRvIII Tumor Xenograft Mouse Model Day -7 Day 0 Day 0, 3, 8, 11, 14, 17 Tumor implantation Subsequent dosing Test article dosing (i.v.) 0 5 10 15 20 25 0 200 400 600 800 1000 1200 1400 1600 1800 Days after treatment Tumor V
Slide 61: PD-1 Agonist Supports Restoration of Homeostasis
61 PD-1 Agonist Supports Restoration of Homeostasis for Inflammatory Diseases
Slide 62: PD-1 Agonist Potentially to Alleviate Inflammatory Disease
62 PD-1 Agonist Potentially to Alleviate Inflammatory Disease Selectively agonize PD-1 without antagonizing the natural PD-1:PD-L1 anti-inflammatory interaction • Rheumatoid arthritis • Broad application in treating inflammatory disease Target mechanism Potential indications Differentiation / opport
Slide 63: Antagonizing PD-1 Worsens Autoimmunity and Systemic Inflammation
PD-1 PD-L1 TCR MHC T-cell Antigen presenting cell 63 Antagonizing PD-1 with PD-L1 Blocking Worsens Autoimmunity and Systemic Inflammation Inflammatory Disease Tissue Healthy Tissue Increased & systemic inflammation No T-cell inhibition No T-cell inhibition Worsened Strong T-cell inhibition Weak T-ce
Slide 64: Agonizing PD-1 Without Blocking PD-L1 Restores T-Cell Suppression
64 Agonizing PD-1 Without Blocking PD-L1 Restores Activated T-Cell Suppression Diseased Tissue Reduced inflammation Healthy Tissue Low-inflammation preserved PD-1 PD-L1 Strong TCR MHC T-cell inhibition T-cell Inflammatory Disease Tissue Healthy Tissue Weak T-cell inhibition Strong T-cell inhibition
Slide 65: In vitro PD-1 Agonism Equals or Surpasses Benchmarks
Benchmark Antibodies PD-1 Agonist Antibodies 65 In vitro PD-1 Agonism Equals or Surpasses Benchmarks and PD-L1 Ab ID EC50 (nM) SD-671823 0.88 SD-300670 0.31 SD-030629 0.36 SD-136366 0.28 SD-759028 0.52 SD-313018 (bispecific) 0.30 AnaptysBio APE12095 17.4 BMS/Celgene PD1AB6 0.76 IgG1 isotype control
Slide 66: Primary T-Cell Suppression Equals or Surpasses Benchmarks
Data on file 66 Primary T-Cell Suppression Equals or Surpasses Benchmarks and PD-L1 IL-2 at 24 hrs. % IL-2 Release Mean of 6 donors 0 100 200 Anti-HEL IgG1 Isotype Control CD69 at 72 hrs. CD69 MFI Mean of 6 donors 0 100 200 300 Anti-HEL IgG1 Isotype Control iBio Molecules Benchmark Molecules Natural